AI assistant
Sending…
IMMUCELL CORP /DE/ — Director's Dealing 2007
Apr 30, 2007
34519_dirs_2007-04-30_b2e230ea-9c6b-4e25-a518-0003c38719d0.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: IMMUCELL CORP /DE/ (ICCC)
CIK: 0000811641
Period of Report: 2007-04-26
Reporting Person: ROTHSCHILD JONATHAN E (Director, 10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2007-04-26 | Common Stock, par value $0.10 per share | P | 100 | $5.79 | Acquired | 389917 | Direct |
| 2007-04-26 | Common Stock, par value $0.10 per share | P | 1800 | $5.80 | Acquired | 391717 | Direct |
| 2007-04-26 | Common Stock, par value $0.10 per share | P | 400 | $5.81 | Acquired | 392117 | Direct |
| 2007-04-26 | Common Stock, par value $0.10 per share | P | 400 | $5.70 | Acquired | 392517 | Direct |
| 2007-04-27 | Common Stock, par value $0.10 per share | P | 1000 | $5.70 | Acquired | 393517 | Direct |
| 2007-04-27 | Common Stock, par value $0.10 per share | P | 200 | $5.68 | Acquired | 393717 | Direct |
| 2007-04-27 | Common Stock, par value $0.10 per share | P | 150 | $5.69 | Acquired | 393867 | Direct |
| 2007-04-30 | Common Stock, par value $0.10 per share | P | 100 | $5.67 | Acquired | 393967 | Direct |
| 2007-04-30 | Common Stock, par value $0.10 per share | P | 100 | $5.7 | Acquired | 394067 | Direct |
| 2007-04-30 | Common Stock, par value $0.10 per share | P | 200 | $5.7 | Acquired | 394267 | Direct |
Footnotes
F1: These shares of common stock were acquired by Arterio, Inc., a corporation owned solely by Mr. Rothschild.
F2: This figure includes 197,150 shares of common stock held by Arterio, Inc., a corporation owned solely by Mr. Rothschild.
More from IMMUCELL CORP /DE/
Regulatory Filings
2026
May 14
Annual Report
2026
May 13
Regulatory Filings
2026
May 8
Proxy Solicitation & Information Statement
2026
Apr 24
Regulatory Filings
2026
Apr 14
Regulatory Filings
2026
Apr 14
Regulatory Filings
2026
Apr 8
Annual Report
2026
Mar 30
Director's Dealing
2026
Mar 25
Director's Dealing
2026
Mar 23